➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
McKinsey
Dow
Moodys
McKesson

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CHLORTHALIDONE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Chlorthalidone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000499 ↗ Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) Completed National Institute on Aging (NIA) Phase 2 1980-09-01 The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints.
NCT00000499 ↗ Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1980-09-01 The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints.
NCT00000513 ↗ Trial of Antihypertensive Intervention Management Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1984-04-01 The objective of the Trial of Antihypertensive Intervention Management (TAIM) was to determine the efficacy of dietary management and/or drug therapy, namely thiazide-like diuretics or a beta-blocker, in the control of mild hypertension. Additionally, the Continuation of the Trial of Antihypertensive Intervention Management (COTAIM) tested the effects of long-term weight reduction, and sodium/potassium changes added to weight reduction, as well as the original drug treatment, on the failure rate of blood pressure control.
NCT00000514 ↗ Systolic Hypertension in the Elderly Program (SHEP) Completed National Institute on Aging (NIA) Phase 3 1984-06-01 The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Chlorthalidone

Condition Name

Condition Name for Chlorthalidone
Intervention Trials
Hypertension 33
Essential Hypertension 8
Cardiovascular Diseases 7
Heart Diseases 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Chlorthalidone
Intervention Trials
Hypertension 41
Cardiovascular Diseases 10
Heart Diseases 7
Diabetes Mellitus 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Chlorthalidone

Trials by Country

Trials by Country for Chlorthalidone
Location Trials
United States 206
Germany 16
Korea, Republic of 13
Brazil 12
Mexico 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Chlorthalidone
Location Trials
Florida 10
Texas 9
Virginia 9
Indiana 8
California 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Chlorthalidone

Clinical Trial Phase

Clinical Trial Phase for Chlorthalidone
Clinical Trial Phase Trials
Phase 4 17
Phase 3 27
Phase 2 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Chlorthalidone
Clinical Trial Phase Trials
Completed 29
Recruiting 12
Not yet recruiting 10
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Chlorthalidone

Sponsor Name

Sponsor Name for Chlorthalidone
Sponsor Trials
Takeda 9
National Heart, Lung, and Blood Institute (NHLBI) 7
Hospital de Clinicas de Porto Alegre 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Chlorthalidone
Sponsor Trials
Other 41
Industry 21
NIH 10
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Colorcon
Harvard Business School
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.